secwatch.observer — SEC 8-K summary
======================================

Issuer:     BNB PLUS CORP. (BNBX)
CIK:        0000744452
Form:       8-K
Filed at:   2025-05-15T23:59:59+00:00
Accession:  0001104659-25-049406
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Applied DNA Q2 fiscal 2025 revenue up 6% to $983k; net loss narrows to $3.3M
----------------------------------------------------------------------------

- Total revenues $983k (+6% YoY); LineaRx up 44% while MDx testing fell 33%.
- Net loss $3.3M vs $4.5M prior year; operating loss $3.5M; adjusted EBITDA -$3.3M.
- Cash $6.8M at quarter end; expects quarterly cash burn to decline starting June 30, 2025.
- GMP Site 1 validated; annual revenue capacity $10M-$30M; new customer orders for LineaDNA.
- Submitted H5N1 diagnostic validation to NYSDOH; investor call on June 3, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/744452/000110465925049406/0001104659-25-049406-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/744452/000110465925049406/tm2515261d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-049406

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer